<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="670">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01988415</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-114-SARA</org_study_id>
    <nct_id>NCT01988415</nct_id>
  </id_info>
  <brief_title>New Treatment Algorithm to Reduce Spherical Aberration After LASIK Correction for Myopia</brief_title>
  <official_title>A Prospective Study to Evaluate the Feasibility of a New Treatment Algorithm for Wavefront-Guided Lasik Correction of Myopic Refractive Errors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to demonstrate that treatments generated by an
      investigational algorithm reduces spherical aberration compared to currently available
      iDesign treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-LASIK induction of spherical aberration is currently among the most prominent
      challenges for refractive surgery. The presence of significant spherical aberration in the
      visual system results in reduced contrast sensitivity, visual symptoms such as &quot;glare&quot; and
      &quot;halos,&quot; and &quot;night myopia&quot; or the induction of myopia under low lighting (larger pupil
      size). A modified Treatment Planning Software (TPS) &quot;VSS-Rx1 OPM software&quot; has been
      developed that uses a modified algorithm (software that designs the LASIK treatment profile)
      to limit the induction of postoperative spherical aberration. Commercially available
      software used to calculate the LASIK treatment profile was used in one eye (active
      comparator [i.e., control]) and VSS-Rx1 OPM software was used in the fellow eye
      (experimental). Subjects were masked to the use of either the commercially available or
      VSS-Rx1 OPM software.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Postoperative Spherical Aberration</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary Efficacy Outcome Measure: mean spherical aberration of eyes treated with the VSS-Rx1 OPM treatment planning software compared to that of eyes treated with the commercial iDesign treatment planning software.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eyes Losing More Than 2 Lines of Best-corrected Distance Visual Acuity</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Primary Safety Outcome Measure: percentage of eyes losing more than 2 lines of best-corrected distance visual acuity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>VSS-Rx1 OPM vs Commercial iDesign Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile in one eye (active comparator [i.e., control]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VSS-Rx1 OPM vs Commercial iDesign Treatment</intervention_name>
    <description>Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).</description>
    <arm_group_label>VSS-Rx1 OPM vs Commercial iDesign Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age at the time of preoperative exam

          -  Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better

          -  Demonstration of refractive stability

          -  Anticipated postoperative stromal bed thickness of at least 250 microns

          -  Willing and able to return for all study examinations

        Exclusion Criteria:

          -  Pregnant, breast-feeding, or intend to become pregnant over the course of the study

          -  Concurrent use of topical or systemic medications that may impair healing

          -  History of prior intraocular or corneal surgery, active ophthalmic disease, or other
             ocular abnormality

          -  Evidence of keratoconus, corneal irregularity, or abnormal topography in the
             operative eye(s)

          -  Known sensitivity or inappropriate responsiveness to any of the medications used in
             the postoperative course
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Tamayo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medico Oftalmologo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gustavo Tamayo, M.D.</name>
      <address>
        <city>Bogota Laser, Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 6, 2016</lastchanged_date>
  <firstreceived_date>November 14, 2013</firstreceived_date>
  <firstreceived_results_date>October 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Myopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VSS-Rx1 OPM vs Commercial iDesign Treatment</title>
          <description>Commercially available software used to calculate the LASIK treatment profile in one eye (active comparator [i.e., control]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">52 eyes of 26 subjects (paired-eyes: commercial and investigational software)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This was a paired-eye study in which treatment of 26 participants included both eyes (52 eyes total). Use of the commercial versus VSS-Rx1 OPM treatment planning software was randomized by eye. One eye of each subject received the investigational treatment and the fellow eye received the commercial treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>VSS-Rx1 OPM vs Commercial iDesign Treatment</title>
          <description>Commercially available software used to calculate the LASIK treatment profile in one eye (active comparator [i.e., control]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29" spread="6.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Colombia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Postoperative Spherical Aberration</title>
        <description>Primary Efficacy Outcome Measure: mean spherical aberration of eyes treated with the VSS-Rx1 OPM treatment planning software compared to that of eyes treated with the commercial iDesign treatment planning software.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis population was all evaluable eyes.</population>
        <group_list>
          <group group_id="O1">
            <title>Commercial iDesign Treatment Planning Software</title>
            <description>Commercial iDesign treatment planning software: perform wavefront-guided LASIK based upon measurements obtained with the iDesign System and the commercial iDesign treatment planning software</description>
          </group>
          <group group_id="O2">
            <title>VSS-Rx1 OPM Treatment Planning Software</title>
            <description>Investigational treatment planning software: perform wavefront-guided LASIK based upon measurements obtained with the iDesign System and the VSS-Rx1 OPM treatment planning software</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes analyzed</title>
            <units>Eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Postoperative Spherical Aberration</title>
            <description>Primary Efficacy Outcome Measure: mean spherical aberration of eyes treated with the VSS-Rx1 OPM treatment planning software compared to that of eyes treated with the commercial iDesign treatment planning software.</description>
            <units>Âµm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.069" spread="0.092"/>
                  <measurement group_id="O2" value="0.016" spread="0.108"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes Losing More Than 2 Lines of Best-corrected Distance Visual Acuity</title>
        <description>Primary Safety Outcome Measure: percentage of eyes losing more than 2 lines of best-corrected distance visual acuity</description>
        <time_frame>3 Months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis population was all evaluable eyes.</population>
        <group_list>
          <group group_id="O1">
            <title>Commercial iDesign Treatment Planning Software</title>
            <description>Commercial iDesign treatment planning software: perform wavefront-guided LASIK based upon measurements obtained with the iDesign System and the commercial iDesign treatment planning software</description>
          </group>
          <group group_id="O2">
            <title>VSS-Rx1 OPM Treatment Planning Software</title>
            <description>Investigational treatment planning software: perform wavefront-guided LASIK based upon measurements obtained with the iDesign System and the VSS-Rx1 OPM treatment planning software</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes analyzed</title>
            <units>Eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Eyes Losing More Than 2 Lines of Best-corrected Distance Visual Acuity</title>
            <description>Primary Safety Outcome Measure: percentage of eyes losing more than 2 lines of best-corrected distance visual acuity</description>
            <units>percentage of eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Commercial iDesign Treatment Planning Software</title>
          <description>Commercial iDesign treatment planning software: perform wavefront-guided LASIK based upon measurements obtained with the iDesign System and the commercial iDesign treatment planning software</description>
        </group>
        <group group_id="E2">
          <title>VSS-Rx1 OPM Treatment Planning Software</title>
          <description>Investigational treatment planning software: perform wavefront-guided LASIK based upon measurements obtained with the iDesign System and the VSS-Rx1 OPM treatment planning software</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor shall have the first right of publication of study data for the first 12 months. The institution or principal investigator may not disclose any of the Sponsor's proprietary information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janice Tarrant</name_or_title>
      <organization>Abbott Medical Optics</organization>
      <phone>408-273-4163</phone>
      <email>janice.tarrant@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
